

The antimicrobial and antibiofilm activity of *Lactobacillus salivarius* and *Lactobacillus casei* against *Escherichia coli*

Rania M. Al-Groom^{1,2*}

¹Department of Medical Laboratory Science, Faculty of Allied Medical Sciences, Zarqa University, 2000 Zarqa 13110, Jordan

²Department of Allied Medical Sciences, Zarqa University College, Al-Balqa Applied University, 2000 Zarqa 13110, Jordan

Abstract: Background: Lactobacilli have been crucial for the production of fermented products for centuries. They are also members of the mutualistic microbiota present in the human gastrointestinal and urogenital tract. Recently, increasing attention has been given to their probiotic, health-promoting capacities. **Objectives:** The purpose of this study was to (a) evaluate the antibacterial and antibiofilm activities of *Lactobacillus salivarius* (ATCC 11741) and *Lactobacillus casei* (ATCC 9595) against *Escherichia coli*; and (b) assess the anti-virulence potential of these probiotics, by examining their impacts on the expression of selected genes in the test organism. **Materials and Methods:** The antibacterial, antibiofilm and antivirulence activities of *L. salivarius* and *L. casei* against *E. coli* were investigated by agar well diffusion, microtiter plate, crystal violet assay, quantitative real-time polymerase chain reaction (qPCR) analysis. **Results:** Susceptibility testing indicated antibacterial and antibiofilm activities of *L. salivarius* and *L. casei* against *E. coli*. Agar inhibition assay showed that *L. salivarius* and *L. casei* has antibacterial activity against *E. coli* with an inhibition zone of 21 ± 2 mm and 24 ± 1 mm respectively. The *L. salivarius* and *L. casei* were found to degrade and inhibit *E. coli* biofilm. All biofilm-forming cells treated with *L. salivarius* and *L. casei* supernatants showed reduced expression of genes involved in biofilm formation and quorum sensing. The expression of *yjfO* (*bsmA*), *csgA*, *ycfR* (*BhsA*), *tnaA*, *lsrA*, and *rpoS* genes of *E. coli* was decreased, 0.75-fold, 0.65-fold, 0.5-fold, 0.73-fold, 1.2-fold and 0.85-fold respectively after exposure to *L. salivarius*, while the expression of *yjfO* (*bsmA*), *csgA*, *ycfR* (*BhsA*), *tnaA*, *lsrA*, and *rpoS* genes of *E. coli* was decreased, 1.0-fold, 0.75-fold, 0.5-fold, 0.82-fold, 1.4-fold and 0.9-fold respectively after exposure to *L. casei*. **Conclusion:** The results of this study indicate that *L. salivarius* and *L. casei* strains showed a good antibacterial and antibiofilm against *E. coli*. Generally, present study suggested that the *L. salivarius* and *L. casei* strains exhibits a good antimicrobial activity.

Keywords: Probiotics, biofilm, gene expression, *E. coli*

Correspondence to: Rania M. Al-Groom, Department of Medical Laboratory Science, Faculty of Allied Medical Sciences, Zarqa University; Department of Allied Medical Sciences, Zarqa University College, Al-Balqa Applied University, Jordan; E-mail: rgroom@zu.edu.jo; raniaalgroup@bau.edu.jo

Received: May 3, 2023; **Accepted:** August 10, 2023; **Published Online:** September 7, 2023

Citation: Al-Groom, R.M., 2023. The antimicrobial and antibiofilm activity of *Lactobacillus salivarius* and *Lactobacillus casei* against *Escherichia coli*. *Applied Environmental Biotechnology*, 8(1): 18-24. <http://doi.org/10.26789/AEB.2023.01.003>

Copyright: The antimicrobial and antibiofilm activity of *Lactobacillus salivarius* and *Lactobacillus casei* against *Escherichia coli*. © 2023 Rania M. Al-Groom. This is an Open Access article published by Urban Development Scientific Publishing Company. It is distributed under the terms of the [Creative Commons Attribution-Noncommercial 4.0 International License](https://creativecommons.org/licenses/by-nc/4.0/), permitting all non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited and acknowledged.

1 Introduction

A new alternative therapy against multidrug-resistant bacteria is required to treat infectious diseases, as biofilm formation is a global public health concern (Aloush et al., 2006; Lara et al., 2010; Subramani et al., 2017). Biofilm is a type of self-produced extracellular matrix, which is embedded by the bacteria to provide a protective environment for them to grow (Colvin et al., 2011; Flemming and Wingender, 2010; Jaffar et al., 2016). One of the resistance abilities of bacteria is achieved by biofilms formation. By definition biofilm is a community of microorganisms usually adhered to a surface and encased in an extracellular polysaccharide matrix (EPS). Biofilms are highly problematic especially in clinical settings due to their disadvantage that causes refractory chronic infections (Bjarnsholt, 2013) especially their ability to tolerate antimicrobial therapy at concentrations up to 1,000 times greater than those required to inhibit planktonic cells (Dosler

and Karaaslan, 2014; Kapoor et al., 2011; Spoering and Lewis, 2001). Therefore, biofilm prolongs the duration of bacterial infections, increases tolerance to antibiotics and provides resistance against phagocytic cells. In addition, biofilm can be formed in a wide range of surfaces both on biotic and abiotic surfaces in humans (Shrout et al., 2011). In the clinic, microbial biofilms through colonization on implants (prosthetic heart valves, catheters and joint replacement) and medical devices, account for hospital-acquired infections that make the patients easily infected by certain pathogens. Moreover, biofilm infections lead to different disorders, for instance, diabetes mellitus, dental caries, medical implants and wound infections that significantly affect the quality of life, cancer development, and subsequently, increase the global morbidity rate (Bjarnsholt et al., 2018). Recent evidence indicates that one of the strongest options for fighting pathogenic biofilms would be probiotics (Barzegari et al., 2020). Probiotics are defined as live microorganisms which

when administered in adequate amounts confer a health benefit on the host (Fang et al., 2018). The possible mechanisms by which probiotics may inhibit enteric pathogens include modification of the host intestinal environment and immune system, competition for nutritional substrates as well as sites of adhesion on intestinal epithelial cells, secretion of antimicrobial compounds and inactivation of toxins (Birošova and Mikulašova, 2009). Earlier studies have reported the use of probiotics in the prevention and treatment of gastrointestinal infections caused by Salmonella (Alcaine et al., 2007). The most extensively studied probiotic strains are reported from genera *Lactobacillus* and *Bifidobacterium*, which are also included in many functional foods and dietary supplements (Frick et al., 2007; Macpherson and Harris, 2004). Probiotics are living bacteria that confer a health-related profit to the host when administered in acceptable doses. This action of probiotics is mediated by interacting with host gut microbiota (Barzegari et al., 2020). *Lactobacillus* (lactic Acid Bacteria, LAB) and *Bifidobacterium* are the most important microbial genera that are generally used in the preparations of probiotics (Barzegari et al., 2020). These strains support a balanced immune function, healthy gut microbiome and improved nutrient absorption and lead to a healthy host (Sánchez et al., 2017). They are also capable to potentially modulate the microbial ecology of biofilms by pathogens' growth inhibition, adhesion and co-aggregation (Barzegari et al., 2020). Furthermore, probiotics exert antimicrobial activities against the gastrointestinal (GI) tract pathogens via declining luminal pH, competing for adhesion sites and nutrients and producing antimicrobial agents such as bacteriocins, hydrogen peroxide and organic acids (Barzegari et al., 2020). Based on these properties, probiotics present effectiveness in managing biofilms. To date, some articles have been published on the beneficial effects of probiotics on the pathogenic biofilms formation in the wound as well as oral and infectious diseases (Barzegari et al., 2020). Thus, treatment for *E. coli* infections often becomes a challenge due to the ability of these bacteria to be resistant to antibiotics via producing strong biofilm (Subedi et al., 2018). Therefore, recent studies are focusing alternative antimicrobial strategies to treat bacterial infections. However, there is a lack of information on the biofilm-associated infections involved in altered virulence properties of *E. coli*. Therefore, this study aimed to evaluate the impact of *Lactobacillus salivarius* (ATCC 11741) and *Lactobacillus casei* (ATCC 9595) on the growth, biofilm formation and gene expression profile of *E. coli*.

2 Materials and Methods

2.1 Bacterial strains and culture conditions

A standard reference of *Escherichia coli* (ATCC 8739) was purchased from American Type Culture Collection (ATCC, USA) and used throughout this study. *E. coli* was streaked on nutrient agar (NA) plate and incubated at 37°C for 24

hours. Then the strain was suspended in brain heart infusion (BHI) broth and incubated at 37°C for 24 hours and stored at 80°C in broth with 30% glycerol (Alfarrayeh et al., 2021; Jeong et al., 2018; Prabhurajeshwar and Chandrakanth, 2019; Shaaban et al., 2020; Wasfi et al., 2018; Yonezawa et al., 2015). The following two probiotic LB strains were used in this study: *Lactobacillus salivarius* (ATCC 11741) and *Lactobacillus casei* (ATCC 9595). The strains were cultured in deMan, Rogosa, and Sharpe (MRS) and brain-heart infusion (BHI) media (BD Difco, Franklin Lakes, NJ) at 37°C for 24 hours (Al-kafaween et al., 2021; Wu et al., 2015).

2.2 Agar diffusion assay

The agar diffusion method for antibacterial screening of probiotics. The antibacterial activity of probiotics on *E. coli* was assessed using an agar diffusion method. *E. coli* was incubated in BHI broth at 37°C for 24 hrs. Melted BHI agar medium held at 45°C was inoculated with *E. coli* at a concentration equivalent to McFarland 0.5 standard (1.5×10^8 CFU/ml). Wells of 7 mm diameter were filled by 150 μ l of each probiotic. Zones of Inhibition was measured using digital callibir after incubating the plates at 37°C for 24 hrs. The experiment was performed in triplicate (Bidossi et al., 2018; Jeong et al., 2018; Lin et al., 2015; Prabhurajeshwar and Chandrakanth, 2019; Wasfi et al., 2018).

2.3 Antibacterial testing of treated and untreated probiotic

To determine the antibacterial activity of each probiotic, *E. coli* was grown overnight at 37°C in BHI broth. The *E. coli* culture was diluted with BHI broth medium to a turbidity equivalent to McFarland 0.5 (1×10^8 cells/ml). Subsequently, 150 μ l of the *E. coli* suspension and 150 μ l of untreated supernatants were added to the wells of 96-well plate for each probiotic. The plates were incubated at 37°C for 24 hrs. In control wells, the probiotic was replaced by sterile MRS broth. The OD_{600 nm} was recorded after incubation using microplate reader. The experiment was performed in triplicate (Jeong et al., 2018; Prabhurajeshwar and Chandrakanth, 2019; Shaaban et al., 2020; Wasfi et al., 2018).

2.4 The effect of probiotics on *E. coli* adherence

This test was performed in a similar manner as the antimicrobial test using BHI medium supplemented with 0.2% sucrose and the reduction in biofilm formation was evaluated by crystal violet assay as previously described. Initially, after incubation, supernatants were removed and media was then removed by invertip the plate and tapping the plate. The plate was washed three times with PBS to remove free-floating planktonic bacteria and drained for drying. The plate was stained with 200 μ l of 0.1% crystal violet for 5 min. Then, the plate was carefully rinsed under running tap water to

remove excess stain, dried at room temperature before solubilizing the biofilm with 95% of ethanol. The absorbance was measured by using a microplate reader at OD₅₇₀. The experiment was performed in triplicate (Alfarrayeh et al., 2021; Bidossi et al., 2018; Carvalho et al., 2021; Fang et al., 2018; He and Ahn, 2011; Ishikawa et al., 2020; Jeong et al., 2018; Lin et al., 2015; Olson et al., 2018; Sánchez et al., 2017; Wasfi et al., 2018).

2.5 The effect of probiotics on *E. coli* biofilm

An overnight culture of *E. coli* was diluted to McFarland 0.5 in BHI supplemented with 0.2% sucrose. This culture was distributed in the 96-well plate by the volume of 200 μ l and incubated at 37°C for 24 hrs. Culture supernatant was removed, and wells were washed with sterile saline. A volume of 200 μ l of untreated supernatant was added in each well and incubated at 37°C for 24 hrs. The absorbance was measured by using a microplate reader OD₅₇₀. The reduction in biofilm formation was determined as previously described. The experiment was performed in triplicate (Alfarrayeh et al., 2021; Bidossi et al., 2018; Carvalho et al., 2021; Fang et al., 2018; He and Ahn, 2011; Ishikawa et al., 2020; Jeong et al., 2018; Lin et al., 2015; Olson et al., 2018; Sánchez et al., 2019; Wasfi et al., 2018).

2.6 Extraction of total bacterial RNA

The effect of probiotics on *E. coli* in the planktonic form and the biofilm form. *E. coli* was grown overnight at 37°C in BHI broth and was diluted to McFarland 0.5. A volume of 200 μ l *E. coli* suspension and 200 μ l of each probiotic were added to 1 ml of BHI broth and were incubated at 37°C for 24 hrs. In control wells, each probiotic supernatant was replaced by MRS broth. After incubation, culture suspension was removed from wells for RNA extraction from planktonic bacteria. Cells adhering to the plate wells were washed twice by sterile saline and then dislodged and suspended in saline by scraping into a centrifuge tube. The total RNA was isolated from *E. coli* planktonic and adherent cells using kit SV Total RNA Isolation System (Promega, UK) according to the manufacturers instructions. The remaining DNA in RNA samples was treated by RNase-free DNase I to eliminate DNA contamination. Agarose gel electrophoresis of RNA samples verified its integrity. RNA concentration and purity were determined by the ND1000 spectrophotometer (NanoDrop). Finally, Total RNA was converted to cDNA following the manufacturers instructions kit (Promega, UK) (He and Ahn, 2011; Ishikawa et al., 2020; Jeong et al., 2018; Prabhurajeshwar and Chandrakanth, 2019; Sánchez et al., 2017; Wasfi et al., 2018; Wasfi et al., 2016).

2.7 Reverse transcription quantitative real-time PCR and data analysis

RT-qPCR was used to examine the effect of probiotics on the expression levels of six target genes [*yjfO* (*bsmA*), *csgA*, *ycfR*

(*BhsA*), *tnaA*, *lsrA* and *rpoS*] involved in biofilm formation, quorum sensing, and stress survival) in *E. coli*. The primers for the qPCR used in the current study (Table 1). Reverse transcription quantitative real-time PCR was performed by Applied Biosystems StepOne. All reactions (20 μ l) were performed using three technical replicates. Each reaction mixture contained 100 ng cDNA and 300 nM primers per reaction. The RT-qPCR cycling conditions were as follows: one cycle with 95°C for 2 min.; then 40 cycles of denaturation at 95°C for 5 sec., annealing at 52-62°C (depending on primers used) for 10 sec., and extension and fluorescent data collection at 72°C for 20 sec. A dissociation curve was generated at the end of each reaction. In all qPCR runs, negative controls without template were run in parallel. The 16s rRNA gene (housekeeping gene) was selected as the internal control. The relative mRNA levels of genes of interest were determined and normalized to the expression of the housekeeping gene using the $2^{-\Delta\Delta Ct}$ value analysis. The qPCR data were expressed as the fold change in expression levels of genes in *E. coli* cells exposed to each probiotics as compared to their levels in the untreated cells. The changes in gene expression were tested in the *E. coli* cells in the planktonic form and the biofilm-forming state. The experiment will be performed in triplicate (He and Ahn, 2011; Shaaban et al., 2020; Jeong et al., 2018; Prabhurajeshwar and Chandrakanth, 2019; Sánchez et al., 2017; Wasfi et al., 2018; Wasfi et al., 2016).

Table 1. Gene specific primers of *E. coli* used for RT-qPCR analysis

Gene name	Amplicon size (bp)	Annealing temp (C°)	Direction primer sequence (5' → 3')
<i>yjfO</i> (<i>bsmA</i>)	76	53	For: CGCCAGTAACGGACCATC Rev: GTGCTTACGCTACCTATTCC
<i>csgA</i>	191	56	For: ATGGCGGCGGTAATGGTG Rev: GTTGACGGAGGAGTTAGATGC
<i>ycfR</i> (<i>BhsA</i>)	81	54	For: CGAAGTTCAGTCAACGCCAGAAG Rev: TCCAGCGATCCCAGATTGTCC
<i>tnaA</i>	174	54	For: CTGGATAGCGAAGATGTG Rev: CCGAATGGTGTATTGATAAC
<i>lsrA</i>	178	54	For: TACTCATAACCTTCGTGGATTCTG Rev: TACTTGGCGGAGGCTTC
<i>rpoS</i>	199	54	For: CTCAACATACGCAACCTG Rev: GTCATCAACTGGCTTATCC
<i>16s rRNA</i> Reference gene	101	52	For: CCTACGGGAGGCAGCAGTAG Rev: CAACAGAGCTTACGATCCGAAA

2.8 Statistical analysis

For all assays, all experiments were performed in triplicate. All data were expressed as mean \pm standard deviation. Independent student t-test from (SPSS version 20) was used to compare between treated and untreated groups. The statistical analyses performed were considered significant when $P < 0.05$.

3 Results

3.1 Agar diffusion assay

The zone of inhibition produced by whole bacterial culture (concentration 1.5×10^8 cells/ml) was larger than that pro-

duced by spent culture supernatant produced by same concentration of cells. This indicates the higher antibacterial effect of whole bacterial culture as compared to the cell-free filtered supernatant. According to the zone of inhibition diameter, the highest antibacterial activities of probiotics was observed with *Lactobacillus casei*, whereas the lowest antibacterial activities was observed with *Lactobacillus salivarius* (Table 2).

Table 2. Growth Inhibition zone (mm) of probiotic against *E. coli*

Strain	Zone of inhibition (mm)	
	Whole bacterial culture *	Spent culture supernatant *
<i>Lactobacillus salivarius</i>	21±2	15±2
<i>Lactobacillus casei</i>	24±1	19±1

Note: The values of means ± S.D. of inhibition zones (mm). * All results were significantly different from control ($P < 0.05$).

3.2 Antibacterial testing of treated and untreated probiotic

The average of optical density (OD) for control sample and tested sample was calculated. As shown in Figure 1, the probiotics (*L. salivarius* and *L. casei*) showed significant inhibitory effect on the growth of *E. coli* ($P < 0.05$). After treated with probiotics the growth of *E. coli* was reduce by measuring the absorbance. There was significant difference in the potency of the inhibitory effect between the two samples ($P > 0.05$). After neutralizing the supernatant, the antimicrobial effect was significantly reduced ($P < 0.05$) compared with untreated supernatant, yet still showing significant reduction ($P < 0.05$) in *E. coli* growth. *L. salivarius* and *L. casei* were showed significant reduction ($P < 0.05$) in its antimicrobial effect on *E. coli* indicating that both probiotics contribute in its antimicrobial effect against *E. coli* (Figure 1).




Figure 1. Optical density (OD) of *E. coli* growth in the presence of *L. salivarius* and *L. casei*. Data are expressed as the mean ± S.D., * $P < 0.05$ compared with *E. coli* growth in broth as control.

3.3 Effect of probiotics on *E. coli* adherence and preformed biofilm

Growth of *E. coli* biofilms in the presence of two probiotics was significantly ($P < 0.05$) reduced relatively to the untreated control. The preformed biofilm was decreased

compared to the untreated control. *L. salivarius* and *L. casei* supernatant caused significant reduction ($P < 0.05$) in *E. coli* adherence and preformed biofilm. Reduction percentages were 78% and 67%, respectively. The effect of *L. casei* supernatant was the least among tested supernatants on adherence as it showed significant effect on the preformed biofilm. The *L. salivarius* and *L. casei* supernatant caused reduction in adherence with percentages of 78% and 67% respectively and reduction in preformed biofilm with percentage of 22% and 33% respectively (Figure 2).





Figure 2. Effect of probiotics on *E. coli* biofilm. (*L. salivarius* and *L. casei*). Control: *E. coli* grown in broth. Data are expressed as the mean ± S.D. * $P < 0.05$, compared with control.

3.4 RT-qPCR analyses

In the current study, qPCR was used to evaluate and compare the impact on *E. coli* cells after exposure to two probiotics (*L. salivarius* and *L. casei*) overnight. The levels of expression of six genes, that have been previously shown to be involved in virulence of the *E. coli* in the planktonic and biofilm-forming cells, were compared to the control untreated cells prepared under the same conditions with and without probiotics. The selected genes included three genes involved in biofilm formation [*yjfO* (*bsmA*), *csgA*, and *ycfR* (*BhsA*)], two genes involved in quorum sensing (*tnaA* and *lsrA*), and one gene associated with stress survival *rpoS*. The ct values between biological replicas were standardized against the reference gene and changes in relative expression to untreated cells were analysed.


As revealed by the independent student t-test from (SPSS version 20), there was a significant overall difference ($P < 0.05$) in the expression of each of the tested genes between the exposed and control group, in both planktonic forms and biofilm-forming cells. All genes, [*yjfO* (*bsmA*), *csgA*, *ycfR* (*BhsA*), *tnaA*, *lsrA*, and *rpoS*] were downregulated following exposure to *L. salivarius* and *L. casei* (Figure 3 and Figure 4). Although different degrees of downregulation were observed following exposure to the *L. salivarius* and *L. casei*. Significant reduction in gene expression of *yjfO* (*bsmA*), *csgA*, *ycfR* (*BhsA*), *tnaA*, *lsrA*, and *rpoS* forming genes was observed in the *E. coli* cells in the presence of *L. salivarius* and *L. casei*.

In the case of *yjfO* (*bsmA*), *csgA*, *ycfR* (*BhsA*), *tnaA*, *lsrA*, and *rpoS* genes, its expression was downregulated following exposure to the *L. salivarius* and *L. casei*. The expression of *yjfO* (*bsmA*), *csgA*, *ycfR* (*BhsA*), *tnaA*, *lsrA*, and *rpoS* genes of *E. coli* were decreased, 0.75-fold, 0.65-fold, 0.5-fold, 0.73-fold, 1.2-fold and 0.85-fold respectively after exposure to *L. salivarius* (Figure 3), while the expression of *yjfO* (*bsmA*), *csgA*, *ycfR* (*BhsA*), *tnaA*, *lsrA*, and *rpoS* genes of *E. coli* were decreased, 1.0-fold, 0.75-fold, 0.5-fold, 0.82-fold, 1.4-fold and 0.9-fold respectively after exposure to *L. casei* (Figure 4)



Note: Mean values of fold changes (\pm SD) are shown in relation to untreated (control) *E. coli* cells. Asterisks indicate statistically significant differences in the expression of each gene between treated samples and control ($*P < 0.05$).

Figure 3. Alterations in gene expression profiles associated with exposure of *E. coli* to *L. salivarius* as determined by qPCR.



Note: Mean values of fold changes (\pm SD) are shown in relation to untreated (control) *E. coli* cells. Asterisks indicate statistically significant differences in the expression of each gene between treated samples and control ($*P < 0.05$).

Figure 4. Alterations in gene expression profiles associated with exposure of *E. coli* to *L. casei* as determined by qPCR.

4 Discussion

Selected probiotics particularly *L. salivarius* and *L. casei* had good inhibitory effects against *E. coli* pathotype (Karimi et al., 2018; Wasfi et al., 2018). Many studies showed growth inhibitory effects of probiotics against different pathogens. Study by Karimi et al., 2018 showed that yogurt consumption causes intestinal colonization of probiotic bacteria such as *Lactobacillus*, and provided conditions to prevent colonization of EHEC (Karimi et al., 2018). Another study showed growth inhibitory effects of probiotic *Lactobacillus casei* and *Enterococcus faecium* against *Listeria monocytogenes*, *Escherichia coli* bacillus cereus and *Salmonella enteritidis* (Hassanzadazar et al., 2014; Hassanzadazar et al., 2012). Obtained results of the present study showed growth inhibitory effects of two probiotics against *E. coli*. Similar studies confirmed antimicrobial effects of culture supernatant of probiotics, for example previous study showed growth inhibitory effects of *L. plantarum* and *L. curvatus* against different pathogens with well diffusion method (Karimi et al., 2018). Matsusaki studied growth inhibitory effects of probiotic *Lactobacillus* with colony count method (Karimi et al., 2018). All of the probiotic tested using plate assays inhibited *E. coli*. The extent of inhibition was dependent on the probiotic strain, such that *L. salivarius* tended to inhibit *E. coli* growth to a greater extent than that observed for the *L. casei*. Based on the results of this study, present probiotic bacteria in natural resources can be used for inhibition and reduction of pathogens, including enteric pathogens and antibacterial effects of their metabolites are active and stable under different conditions of temperature and acidity. A variety of genes have been shown to be important in *E. coli* fitness and pathogenicity, and thus modulating the expression of these genes can add to the effectiveness of antimicrobial therapy. Six of these genes, which are involved in biofilm formation, quorum sensing, and stress survival in *E. coli*, were selected for this study, and their differential gene expression profiles in response to exposure to the tested probiotics were determined using qPCR.

A number of genes included three genes involved in biofilm formation [*yjfO* (*bsmA*), *csgA*, and *ycfR* (*BhsA*)], two genes involved in quorum sensing (*tnaA* and *lsrA*), and one gene associated with stress survival *rpoS* in *E. coli* (Alkafaween et al., 2021). The current results showed that all genes were downregulated after exposure to *L. salivarius* and *L. casei* with different degrees of downregulation. This pattern of expression was the same regardless of the probiotics. Therefore, the current findings may suggest that the both probiotics under study can prevent or disrupt *E. coli* biofilms. It has to be noted that the biological relevance of downregulating the above-mentioned genes may not be strictly limited to biofilm disruption, with a possibility to affect multiple cellular processes. Previous study mentioned that the mutation of the *yjfO* gene in *E. coli* has been shown to cause alteration of cell motility, increased sensitivity to pH

and oxidative stresses, and reduction of viability, rather than only affecting the biofilm formation (Lee et al., 2011). A set of genes have been previously shown to play an important role in the quorum-sensing network in *E. coli*, such as the *tnaA* and *lsrA* genes (Wasfi et al., 2016). The present results showed that both genes were downregulated in response to all the tested probiotics. It is tempting to speculate that the tested probiotics may act as quorum-sensing inhibitors, and thus may have the potential to decrease the virulence of pathogens like *E. coli*, by interrupting their cellular communication system.

5 Conclusion

In conclusion, with increasing rates of antimicrobial resistance in important pathogens, there is a growing interest in the targeted application of lactobacilli against pathogens. This study has shown that both lactobacilli *L. salivarius* and *L. casei* can inhibit *E. coli*. The current study suggested that the *Lactobacillus* strains in the present study displayed potential probiotic properties. These strains had significant antimicrobial effect against *E. coli*. Moreover, we showed the antibiofilm effect of *Lactobacillus* strains against *E. coli*. The effects of *L. salivarius* and *L. casei* probiotics provides antibacterial effect against pathogenic bacteria. The results of this study indicated that *L. salivarius* and *L. casei* probiotics directly inhibit growth and biofilm of *E. coli* by reduced the level of gene expression of various genes in *E. coli*. However, further studies are needed to investigate probiotic characteristics of various *Lactobacillus* strains.

Acknowledgments

This work was supported by the Deanship of Scientific Research at Zarqa University.

Conflict of Interest

There is no conflict of interest to be declared.

References

- Al-kafaween, M.A., Mohd Hilmi, A.B., Nagi Al-Jamal, H.A., Jaffar, N., Al-Sayyed, H., Zahri, M.K., 2021. Effects of Selected Malaysian Kelulut Honey on Biofilm Formation and the Gene Expression Profile of *Staphylococcus Aureus*, *Pseudomonas Aeruginosa* and *Escherichia coli*. *Jordan Journal of Pharmaceutical Sciences*, 14(1).
- Al-Kafaween, M.A., Hilmi, A.B.M., Khan, R.S., Bouacha, M., Amonov, M., 2019. Effect of Trigona honey on *Escherichia coli* cell culture growth: In vitro study. *Journal of Apitherapy*, 5(2): 10-17. <https://doi.org/10.5455/ja.20190407083601>
- Alcaine, S.D., Warnick, L.D., Wiedmann, M., 2007. Antimicrobial resistance in nontyphoidal *Salmonella*. *Journal of food protection*, 70(3): 780-790. <https://doi.org/10.4315/0362-028X-70.3.780>
- Alfarrayeh, I., Fekete, C., Gazdag, Z., Papp, G., 2021. Propolis ethanolic extract has double-face in vitro effect on the planktonic growth and biofilm formation of some commercial probiotics. *Saudi Journal of Biological Sciences*, 28(1): 1033-1039. <https://doi.org/10.1016/j.sjbs.2020.11.047>
- Aloush, V., Navon-Venezia, S., Seigman-Igra, Y., Cabili, S., Carmeli, Y., 2006. Multidrug-resistant *Pseudomonas aeruginosa*: risk factors and clinical impact. *Antimicrobial agents and chemotherapy*, 50(1): 43-48. <https://doi.org/10.1128/AAC.50.1.43-48.2006>
- Barzegari, A., Kheyrolahzadeh, K., Khatibi, S.M.H., Sharifi, S., Memar, M.Y., Vahed, S.Z., 2020. The battle of probiotics and their derivatives against biofilms. *Infection and drug resistance*, 13: 659. <https://doi.org/10.2147/IDR.S232982>
- Bidossi, A., De Grandi, R., Toscano, M., Bottagisio, M., De Vecchi, E., Gelardi, M., Drago, L., 2018. Probiotics *Streptococcus salivarius* 24SMB and *Streptococcus oralis* 89a interfere with biofilm formation of pathogens of the upper respiratory tract. *BMC infectious diseases*, 18(1): 1-11. <https://doi.org/10.1186/s12879-018-3576-9>
- Birošova, L. and Mikulašova, M., 2009. Development of triclosan and antibiotic resistance in *Salmonella enterica* serovar Typhimurium. *Journal of Medical Microbiology*, 58(4): 436-441. <https://doi.org/10.1099/jmm.0.003657-0>
- Bjarnsholt, T., 2013. The role of bacterial biofilms in chronic infections. *Apmis*, 121: 1-58. <https://doi.org/10.1111/apm.12099>
- Bjarnsholt, T., Buhlin, K., Dufrière, Y., Gomelsky, M., Moroni, A., Ramstedt, M., Åkerlund, B., 2018. Biofilm formation-what we can learn from recent developments: Wiley Online Library. <https://doi.org/10.1111/joim.12782>
- Carvalho, F.M., Teixeira-Santos, R., Mergulhão, F.J., Gomes, L.C., 2021. The Use of Probiotics to Fight Biofilms in Medical Devices: A Systematic Review and Meta-Analysis. *Microorganisms*, 9(1): 27. <https://doi.org/10.3390/microorganisms9010027>
- Colvin, K.M., Gordon, V.D., Murakami, K., Borlee, B.R., Wozniak, D.J., Wong, G.C., Parsek, M.R., 2011. The pel polysaccharide can serve a structural and protective role in the biofilm matrix of *Pseudomonas aeruginosa*. *PLoS Pathog*, 7(1): e1001264. <https://doi.org/10.1371/journal.ppat.1001264>
- Dosler, S. and Karaaslan, E., 2014. Inhibition and destruction of *Pseudomonas aeruginosa* biofilms by antibiotics and antimicrobial peptides. *Peptides*, 62: 32-37. <https://doi.org/10.1016/j.peptides.2014.09.021>
- Fang, K., Jin, X., Hong, S.H., 2018. Probiotic *Escherichia coli* inhibits biofilm formation of pathogenic *E. coli* via extracellular activity of DegP. *Scientific reports*, 8(1): 1-12. <https://doi.org/10.1038/s41598-018-23180-1>
- Flemming, H.-C. and Wingender, J., 2010. The biofilm matrix. *Nature reviews microbiology*, 8(9): 623-633. <https://doi.org/10.1038/nrmicro2415>
- Frick, J.-S., Schenk, K., Quitadamo, M., Kahl, F., Köberle, M., Bohn, E., Autenrieth, I.B., 2007. *Lactobacillus fermentum* attenuates the proinflammatory effect of *Yersinia enterocolitica* on human epithelial cells. *Inflammatory bowel diseases*, 13(1): 83-90. <https://doi.org/10.1002/ibd.20009>
- Hassanzadazar, H., Ehsani, A., Mardani, K., 2014. Antibacterial activity of *Enterococcus faecium* derived from Koopeh cheese against *Listeria monocytogenes* in probiotic ultra-filtrated cheese. Paper presented at the Veterinary research forum: an international quarterly journal.
- Hassanzadazar, H., Ehsani, A., Mardani, K., Hesari, J., 2012. Investigation of antibacterial, acid and bile tolerance properties of lactobacilli isolated from Koozeh cheese. Paper presented at the Veterinary Research Forum.
- He, X. and Ahn, J., 2011. Differential gene expression in planktonic and biofilm cells of multiple antibiotic-resistant *Salmonella* Typhimurium and *Staphylococcus aureus*. *FEMS microbiology letters*, 325(2): 180-188. <https://doi.org/10.1111/j.1574-6968.2011.02429.x>
- Ishikawa, K.H., Mita, D., Kawamoto, D., Nicoli, J.R., Albuquerque-Souza, E., Lorenzetti Simionato, M.R., Mayer, M.P.A., 2020. Probiotics alter biofilm formation and the transcription of *Porphyromonas gingivalis* virulence-associated genes. *Journal of oral microbiology*, 12(1): 1805553. <https://doi.org/10.1080/20002297.2020.1805553>

- Jaffar, N., Miyazaki, T., Maeda, T., 2016. Biofilm formation of periodontal pathogens on hydroxyapatite surfaces: Implications for periodontium damage. *Journal of Biomedical Materials Research Part A*, 104(11): 2873-2880.
<https://doi.org/10.1002/jbm.a.35827>
- Jeong, D., Kim, D.-H., Song, K.-Y., Seo, K.-H., 2018. Antimicrobial and anti-biofilm activities of *Lactobacillus kefirifaciens* DD2 against oral pathogens. *Journal of oral microbiology*, 10(1): 1472985.
<https://doi.org/10.1080/20002297.2018.1472985>
- Kapoor, R., Wadman, M.W., Dohm, M.T., Czyzewski, A.M., Spormann, A.M., Barron, A.E., 2011. Antimicrobial peptoids are effective against *Pseudomonas aeruginosa* biofilms. *Antimicrobial agents and chemotherapy*.
<https://doi.org/10.1128/AAC.01516-10>
- Karimi, S., Azizi, F., Nayeb-Aghae, M., Mahmoodnia, L., 2018. The antimicrobial activity of probiotic bacteria *Escherichia coli* isolated from different natural sources against hemorrhagic *E. coli* O157: H7. *Electronic physician*, 10(3): 6548.
<https://doi.org/10.19082/6548>
- Lara, H.H., Ayala-Nez, N.V., Turrent, L.I., Padilla, C.R., 2010. Bactericidal effect of silver nanoparticles against multidrug-resistant bacteria. *World Journal of Microbiology and Biotechnology*, 26(4): 615-621.
<https://doi.org/10.1007/s11274-009-0211-3>
- Lee, J.-H., Park, J.-H., Kim, J.-A., Neupane, G.P., Cho, M.H., Lee, C.-S., Lee, J., 2011. Low concentrations of honey reduce biofilm formation, quorum sensing, and virulence in *Escherichia coli* O157: H7. *Biofouling*, 27(10): 1095-1104.
<https://doi.org/10.1080/08927014.2011.633704>
- Lin, X., Chen, X., Chen, Y., Jiang, W., Chen, H., 2015. The effect of five probiotic lactobacilli strains on the growth and biofilm formation of *S. treptococcus mutans*. *Oral diseases*, 21(1): e128-e134.
<https://doi.org/10.1111/odi.12257>
- Macpherson, A.J. and Harris, N.L., 2004. Interactions between commensal intestinal bacteria and the immune system. *Nature Reviews Immunology*, 4(6): 478-485.
<https://doi.org/10.1038/nri1373>
- Olson, J.K., Navarro, J.B., Allen, J.M., McCulloh, C.J., Mashburn-Warren, L., Wang, Y., Besner, G.E., 2018. An enhanced *Lactobacillus reuteri* biofilm formulation that increases protection against experimental necrotizing enterocolitis. *American Journal of Physiology-Gastrointestinal and Liver Physiology*, 315(3): G408-G419.
<https://doi.org/10.1152/ajpgi.00078.2018>
- Prabhurajeshwar, C. and Chandrakanth, K., 2019. Evaluation of antimicrobial properties and their substances against pathogenic bacteria in-vitro by probiotic *Lactobacilli* strains isolated from commercial yoghurt. *Clinical Nutrition Experimental*, 23: 97-115.
<https://doi.org/10.1016/j.yclnex.2018.10.001>
- Sánchez, B., Delgado, S., Blanco-Míguez, A., Loureno, A., Gueimonde, M., Margolles, A., 2017. Probiotics, gut microbiota, and their influence on host health and disease. *Molecular nutrition and food research*, 61(1): 1600240.
<https://doi.org/10.1002/mnfr.201600240>
- Sánchez, M.C., Romero-Lastra, P., Ribeiro-Vidal, H., Llama-Palacios, A., Figuero, E., Herrera, D., Sanz, M., 2019. Comparative gene expression analysis of planktonic *Porphyromonas gingivalis* ATCC 33277 in the presence of a growing biofilm versus planktonic cells. *BMC microbiology*, 19(1): 1-11.
<https://doi.org/10.1186/s12866-019-1423-9>
- Shaaban, M., El-Rahman, O.A.A., Al-Qaidi, B., Ashour, H.M., 2020. Antimicrobial and Antibiofilm Activities of Probiotic *Lactobacilli* on Antibiotic-Resistant *Proteus mirabilis*. *Microorganisms*, 8(6): 960.
<https://doi.org/10.3390/microorganisms8060960>
- Shrout, J.D., Tolker-Nielsen, T., Givskov, M., Parsek, M.R., 2011. The contribution of cell-cell signaling and motility to bacterial biofilm formation. *MRS bulletin*, 36(5): 367-373.
<https://doi.org/10.1557/mrs.2011.67>
- Spoeing, A.L. and Lewis, K., 2001. Biofilms and planktonic cells of *Pseudomonas aeruginosa* have similar resistance to killing by antimicrobials. *Journal of Bacteriology*, 183(23): 6746-6751.
<https://doi.org/10.1128/JB.183.23.6746-6751.2001>
- Subedi, D., Vijay, A.K., Willcox, M., 2018. Overview of mechanisms of antibiotic resistance in *Pseudomonas aeruginosa*: an ocular perspective. *Clinical and Experimental Optometry*, 101(2): 162-171.
<https://doi.org/10.1111/cxo.12621>
- Subramani, R., Narayanasamy, M., Feussner, K.-D., 2017. Plant-derived antimicrobials to fight against multi-drug-resistant human pathogens. *3 Biotech*, 7(3): 172.
<https://doi.org/10.1007/s13205-017-0848-9>
- Wasfi, R., Abd El-Rahman, O.A., Zafer, M.M., Ashour, H.M., 2018. Probiotic *Lactobacillus* sp. inhibit growth, biofilm formation and gene expression of caries-inducing *Streptococcus mutans*. *Journal of cellular and molecular medicine*, 22(3): 1972-1983.
<https://doi.org/10.1111/jcmm.13496>
- Wasfi, R., Elkhatab, W.F., Khairalla, A.S., 2016. Effects of selected Egyptian honeys on the cellular ultrastructure and the gene expression profile of *Escherichia coli*. *PloS one*, 11(3): e0150984.
<https://doi.org/10.1371/journal.pone.0150984>
- Wu, C.C., Lin, C.T., Wu, C.Y., Peng, W.S., Lee, M.J., Tsai, Y.C., 2015. Inhibitory effect of *Lactobacillus salivarius* on *Streptococcus mutans* biofilm formation. *Molecular oral microbiology*, 30(1): 16-26.
<https://doi.org/10.1111/omi.12063>
- Yonezawa, H., Osaki, T., Kamiya, S., 2015. Biofilm formation by *Helicobacter pylori* and its involvement for antibiotic resistance. *BioMed research international*, 2015.
<https://doi.org/10.1155/2015/914791>